Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 49% Improvement Relative Risk Ventilation 30% c19early.org/e Banaser et al. Aspirin for COVID-19 META ANALYSIS Favors aspirin Favors control
A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19
Banaser et al., International Journal of Medicine in Developing Countries, doi:10.24911/IJMDC.51-1640383699 (meta analysis)
Banaser et al., A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19, International Journal of Medicine in Developing Countries, doi:10.24911/IJMDC.51-1640383699 (meta analysis)
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis of 8 studies showing significantly lower mortality and mechanical ventilation with low dose aspirin.
Currently there are 64 aspirin studies and meta analysis shows:
OutcomeImprovement
Mortality12% lower [6‑18%]
Ventilation5% lower [-6‑15%]
ICU admission4% lower [-13‑18%]
Hospitalization2% higher [-4‑8%]
Cases10% fewer [-6‑24%]
risk of death, 49.0% lower, RR 0.51, p < 0.001.
risk of mechanical ventilation, 30.0% lower, RR 0.70, p = 0.006.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Banaser et al., 24 Dec 2021, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Manal Banaser et al, 2022;6(3):526–534. https://doi.org/10.24911/IJMDC.51-1640383699 International Journal of Medicine in Developing Countries REVIEW ARTICLE A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19 Manal Banaser1* , Mutaman Jarrar2,3, Ayed Alqahtani4, Abdulelah Banaser5, Waleed Albaker6 ABSTRACT COVID-19 pandemic has increased thrombotic risk by 35%. This pandemic led to millions of deaths due to various comorbidities and organ failure. Repurposing aspirin usage to manage COVID-19 hospitalized patients is a logical approach for preventing cardiovascular disease and comorbidities that increase mortality risk. However, several earlier investigations found inconsistent outcomes. This study aims to assess primary and secondary effects in COVID-19 patients with or without aspirin. We performed a multi-database electronic search including Cochrane, Embase, Scopus, and PubMed from date of inception to November 2021 using search terms: (“Coronavirus Disease 2019” OR “COVID-19” OR “SARS-CoV-2” OR “2019-nCoV”) AND (“Acetylsalicylic acid” OR “acetylsalicylate” OR “aspirin” OR “antiplatelet”) AND (“mortality” OR “severe” OR “severity”). Eight retrospective studies met the study criteria comprising 7,171 aspirin users and 8,327 non-aspirin users in COVID19. Aspirin administration significantly reduces mortality risk (RR: 0.51, 95% CI: 0.46-0.57, I2 = 85.05, p-value <0.001, τ2 = 0.028, Z-value: -11.44, p-value <0.001). Aspirin used in COVID-19 patients demonstrated reduced bleeding risk (RR: 0.80, 95 CI%: 0.34-1.9) and reduced risk for the necessity of mechanical ventilation (RR: 0.70; 95% CI: 0.54-0.90, I2 = 0%, p-value: 0.41, τ2 = 0%) when compared with COVID-19 patients without aspirin use. The present review found administration of a low dose of aspirin in COVID-19 patients significantly reduced mortality risk. Keywords: Low dose aspirin, mortality, COVID-19, thrombosis, antiplatelet drug.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit